Neurocrine Biosciences | Frais De Vente Et D'Administration



Selling And Administration Expenses Changement Date
AbbVie USD 3.25B 40M 2025-06
Acadia Pharmaceuticals USD 126.37M 3.71M 2025-03
Agios Pharmaceuticals USD 45.87M 4.34M 2025-06
ALKERMES USD 153.87M 17.83M 2025-06
Alnylam Pharmaceuticals USD 323.31M 83.36M 2025-06
Amgen USD 1.69B 191M 2025-03
Biogen USD 583.8M 11.3M 2025-06
BioMarin Pharmaceutical USD 206.12M 50.65M 2025-03
Cytokinetics USD 57.37M 4.97M 2025-03
Dynavax Technologies USD 106.33M 64.74M 2025-03
Exelixis USD 134.86M 2.32M 2025-07
Gilead Sciences USD 1.26B 603M 2025-03
Halozyme Therapeutics USD 42.36M 113K 2025-03
Incyte USD 331.02M 5.33M 2025-06
Ionis Pharmaceuticals USD 90.6M 14.6M 2025-06
Neurocrine Biosciences USD 286.3M 9.8M 2025-06
Pfizer USD 3.01B 1.27B 2025-03
Prothena USD 16.85M 88K 2024-12
Regeneron Pharmaceuticals USD 634.2M 1.2M 2025-06
Repligen USD 71.23M 28K 2025-06
Sarepta Therapeutics USD 133.63M 30.24M 2025-03
Teva Pharmaceutical Industries USD 959M 40M 2025-06
Ultragenyx Pharmaceutical USD 87.8M 5.3M 2025-03
Vertex Pharmaceuticals USD 424.6M 28.2M 2025-06


Neurocrine Biosciences Frais De Vente Et D'Administration - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Aug 2025.